Pfizer – 2023 Global Migraine ASPIRE – Competitive Research Grant Programusing Expert Review Panel- LOI

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within Unit

Memorial Deadline: Friday 24th, February 2023

External Deadline: Wednesday 1st, March 2023


PLEASE NOTE: Pfizer has extended this deadline to March 1, 2023. 

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.


Geographic Scope: Global

Clinical Area: Migraine

Link to full RFP: 2023 Global Migraine ASPIRE

Specific Area of Interest: The intent of this Request for Proposal (RFP) is to support:

  • Research on the therapeutic application of an oral CGRP antagonist, rimegepant, in migraine, headache, and other diseases where CGRP antagonism may be of clinical benefit
  • The development of tools for clinicians and patients to improve the care of migraine patients
  • Research regarding health disparities associated with migraine

Key Dates:

– RFP release date: December 7, 2022
– LOI due date: February 15, 2023 [Please note the deadline is 23:59 Eastern Time (New York, GMT -5).]
– Review of LOIs by ERP: March 2023
– Anticipated LOI Notification Date: April 2023
– Full Proposal Deadline: *May 2023 [Please note the deadline is 23:59 Eastern Time (New York, GMT -5).]

*Only accepted LOIs will be invited to submit full proposals

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: February 6, 2023